<code id='A47AC5DC49'></code><style id='A47AC5DC49'></style>
    • <acronym id='A47AC5DC49'></acronym>
      <center id='A47AC5DC49'><center id='A47AC5DC49'><tfoot id='A47AC5DC49'></tfoot></center><abbr id='A47AC5DC49'><dir id='A47AC5DC49'><tfoot id='A47AC5DC49'></tfoot><noframes id='A47AC5DC49'>

    • <optgroup id='A47AC5DC49'><strike id='A47AC5DC49'><sup id='A47AC5DC49'></sup></strike><code id='A47AC5DC49'></code></optgroup>
        1. <b id='A47AC5DC49'><label id='A47AC5DC49'><select id='A47AC5DC49'><dt id='A47AC5DC49'><span id='A47AC5DC49'></span></dt></select></label></b><u id='A47AC5DC49'></u>
          <i id='A47AC5DC49'><strike id='A47AC5DC49'><tt id='A47AC5DC49'><pre id='A47AC5DC49'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:48882
          Daphne Koller -- biotech coverage from STAT
          Daphne Koller, early biotech AI entrant Insitro's founder, CEO and board member. Courtesy Jerrick Mitra/Insitro

          New artificial intelligence technologies made headlines last year for their ability to do everything from generating fake musical duets to understanding how proteins fold. But in biotech, one of the most well-funded AI players has been quiet.

          Insitro, a South San Francisco firm, was founded in 2018 by Daphne Koller, who had previously been a Stanford professor, a 2004 MacArthur “genius” grant recipient, and the co-founder and co-CEO of the online course company Coursera. It raised more than $643 million in venture capital, according to PitchBook, from investors including T. Rowe Price, ARCH Venture Partners, and Casdin Capital. The company now has more than 260 employees spread out over 107,000 square feet of laboratory and office space.

          advertisement

          But what exactly is Koller building?

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Diverse clinical trials: Why aren’t we there yet?
          Diverse clinical trials: Why aren’t we there yet?

          KeishaOkaforforSTATClinicaltrialsarecriticaltoadvancinglifesavingmedicationsandtreatments.ButtheU.S.

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb